tiprankstipranks
Trending News
More News >
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
US Market
Advertisement

Jasper Therapeutics (JSPR) AI Stock Analysis

Compare
1,008 Followers

Top Page

JSPR

Jasper Therapeutics

(NASDAQ:JSPR)

Rating:35Underperform
Price Target:
Jasper Therapeutics faces significant financial challenges with a lack of revenue and ongoing losses, leading to a low financial performance score. The technical analysis indicates bearish momentum, and the negative valuation metrics highlight the stock's unattractiveness. Without earnings call data or notable corporate events, the overall outlook remains concerning.
Positive Factors
Analyst Rating
Analyst reiterates a Buy rating with a new $20 PT.
Clinical Trial Results
Efficacy continues to be compelling, with CR rates ranging from 73-89% across the 180mg Q8W OLE and 240mg/360mg single dose cohorts.
Leadership
Dr. Daniel Adelman, an experienced clinical development executive, will assume the role of acting CMO, bringing expertise in immunology and asthmatic conditions.
Negative Factors
Development Delays
The company is now 3-6 months behind its original guidance for initiating the Phase 2b trial in CSU.
Manufacturing Issues
The potential manufacturing issue and underlying uncertainty make it challenging to separate the signal from the noise.
Workforce Reduction
The company announced a 50% reduction in its workforce, leading to a new headcount of about 22 employees, as a measure to extend the cash runway into 2026.

Jasper Therapeutics (JSPR) vs. SPDR S&P 500 ETF (SPY)

Jasper Therapeutics Business Overview & Revenue Model

Company DescriptionJasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
How the Company Makes MoneyJasper Therapeutics makes money primarily through the development and commercialization of its proprietary therapies. Revenue streams include potential licensing agreements, partnerships with pharmaceutical companies, and the eventual sales of approved products. The company may also receive funding through research grants and collaboration agreements which support the advancement of its clinical trials. Strategic partnerships with other biotech and pharmaceutical companies contribute significantly to its revenue by providing both financial support and collaborative opportunities to expand its research and development capabilities.

Jasper Therapeutics Financial Statement Overview

Summary
Jasper Therapeutics' financial position is precarious, characterized by a lack of revenue, substantial operating losses, and reliance on external financing. While the balance sheet appears stable for now, continuous cash burn and no revenue generation may challenge future viability. The company must achieve revenue generation to improve financial health and sustainability.
Income Statement
5
Very Negative
Jasper Therapeutics has consistently reported zero revenue, indicating a lack of commercialized products or services. The company has significant and increasing EBIT and net losses, reflecting high operational costs without offsetting income. This performance suggests severe profitability challenges and raises concerns about long-term sustainability.
Balance Sheet
45
Neutral
The company maintains a relatively healthy equity position, with stockholders' equity exceeding total liabilities, resulting in a low debt-to-equity ratio. However, the absence of revenue and ongoing losses are depleting equity, posing risks to future financial stability.
Cash Flow
20
Very Negative
Jasper Therapeutics reports negative operating and free cash flows, reflecting cash burn without revenue generation. Financing activities, primarily through equity financing, have been necessary to support operations. The lack of cash flow from operations presents a significant risk to liquidity and solvency.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit0.00-1.11M-1.31M-566.00K-21.00K
EBITDA-71.39M-64.98M-38.21M-31.17M-31.95M
Net Income-71.27M-64.47M-37.69M-30.64M-31.67M
Balance Sheet
Total Assets79.90M94.89M48.36M93.65M23.36M
Cash, Cash Equivalents and Short-Term Investments71.64M86.89M38.25M84.70M19.84M
Total Debt1.81M2.79M3.65M2.88M1.62M
Total Liabilities18.23M16.45M12.37M24.14M58.49M
Stockholders Equity61.67M78.44M35.99M69.52M-35.13M
Cash Flow
Free Cash Flow-63.15M-52.33M-46.43M-36.11M-18.27M
Operating Cash Flow-62.60M-52.07M-45.86M-33.68M-18.27M
Investing Cash Flow-532.00K-267.00K-576.00K-2.43M198.34K
Financing Cash Flow47.88M100.97M55.00K100.97M11.29M

Jasper Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.13
Price Trends
50DMA
4.85
Negative
100DMA
4.81
Negative
200DMA
10.26
Negative
Market Momentum
MACD
-0.57
Positive
RSI
34.42
Neutral
STOCH
17.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JSPR, the sentiment is Negative. The current price of 3.13 is below the 20-day moving average (MA) of 4.12, below the 50-day MA of 4.85, and below the 200-day MA of 10.26, indicating a bearish trend. The MACD of -0.57 indicates Positive momentum. The RSI at 34.42 is Neutral, neither overbought nor oversold. The STOCH value of 17.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JSPR.

Jasper Therapeutics Risk Analysis

Jasper Therapeutics disclosed 82 risk factors in its most recent earnings report. Jasper Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Jasper Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$17.07B6.10-7.44%2.88%11.55%-28.15%
57
Neutral
$79.60M-46.28%-33.00%54.91%
44
Neutral
$82.66M-157.73%104.78%40.41%
42
Neutral
$57.07M-62.38%178.84%-40.60%
35
Underperform
$49.12M-101.34%21.40%
$78.54M-67.13%
39
Underperform
$149.31M-73.85%-40.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JSPR
Jasper Therapeutics
3.13
-18.13
-85.28%
VTGN
VistaGen Therapeutics
2.71
-0.93
-25.55%
CBUS
Cibus
1.65
-8.32
-83.45%
IFRX
InflaRx
0.85
-0.68
-44.44%
RENB
Renovaro Biosciences
0.32
-0.93
-74.40%
CABA
Cabaletta Bio
1.66
-5.09
-75.41%

Jasper Therapeutics Corporate Events

Private Placements and Financing
Jasper Therapeutics Signs New Sales Agreement with Jefferies
Neutral
Mar 19, 2025

On March 19, 2025, Jasper Therapeutics entered into a Sales Agreement with Jefferies LLC to potentially sell up to $100 million in common stock, providing flexibility in capital raising. The company also terminated its previous sales agreement with Cantor Fitzgerald & Co. on March 14, 2025, without incurring material penalties, having not sold any shares under that agreement.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025